{"id":1278,"date":"2024-03-22T07:45:00","date_gmt":"2024-03-22T07:45:00","guid":{"rendered":"https:\/\/oncopeptides.com\/mfn_news\/oncopeptides-ab-biostock-investor-pitch-oncopeptides\/"},"modified":"2026-02-23T13:17:59","modified_gmt":"2026-02-23T13:17:59","slug":"oncopeptides-ab-biostock-investor-pitch-oncopeptides","status":"publish","type":"mfn_news","link":"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-ab-biostock-investor-pitch-oncopeptides\/","title":{"rendered":"Oncopeptides AB: BioStock Investor Pitch: Oncopeptides"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong><\/p>\n<p class=\"mfn-wp-retain\">Oncopeptides &auml;r i kommersialiseringsfasen med Pepaxti inom multipelt myelom. 2022 erh&ouml;lls marknadsgodk&auml;nnande och man har hittills lanserat i Tyskland och Grekland, med Spanien n&auml;st p&aring; tur. Nu tar bolaget in ca 300 Mkr i en f&ouml;retr&auml;desemission f&ouml;r att finansiera den fortsatta kommersialiseringen tills dess att man n&aring;r kassafl&ouml;despositivit, vilket f&ouml;rv&auml;ntas ske 2026.&nbsp;Se vd&nbsp;Sofia Heigis&nbsp;ber&auml;tta om v&auml;gen mot m&aring;let i BioStock Studio.<\/p>\n<p><\/strong><\/div>\n<p class=\"mfn-wp-retain\">Se hela presentationen p&aring; biostock.se&nbsp;(<a href=\"https:\/\/www.biostock.se\/\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.biostock.se\/<\/a>):<\/p>\n<p class=\"mfn-wp-retain\"><a href=\"https:\/\/www.biostock.se\/2024\/03\/biostock-investor-pitch-oncopeptides\/\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.biostock.se\/2024\/03\/biostock-investor-pitch-oncopeptides\/<\/a><\/p>\n<p class=\"mfn-wp-retain\">Detta &auml;r ett pressmeddelande fr&aring;n&nbsp;BioStock&nbsp;&#8211; Connecting Innovation &amp; Capital.&nbsp;<a href=\"https:\/\/www.biostock.se\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.biostock.se<\/a><\/p>\n<p class=\"mfn-wp-retain\">Detta material har uppr&auml;ttats i marknadsf&ouml;ringssyfte och &auml;r inte och ska inte anses utg&ouml;ra ett prospekt enligt g&auml;llande lagar och regler. De fullst&auml;ndiga villkoren f&ouml;r f&ouml;retr&auml;desemissionen och mer information om bolaget kommer att redovisas i ett emissionsprospekt som &auml;r planerat att offentligg&ouml;ras den 17 april 2024.&nbsp;<\/p>\n<div class=\"mfn-footer\"><\/div>\n<script>\n                Array.prototype.slice.call(document.querySelectorAll(\".mfn-footer.mfn-attachment\")).forEach(function (el) { el.remove() });\n            <\/script>\n        <div class=\"mfn-attachments-container\"><\/div>","protected":false},"excerpt":{"rendered":"<p>Oncopeptides &auml;r i kommersialiseringsfasen med Pepaxti inom multipelt myelom. 2022 erh&ouml;lls marknadsgodk&auml;nnande och man har hittills lanserat i Tyskland och Grekland, med Spanien n&auml;st p&aring; tur. Nu tar bolaget in ca 300 Mkr i en f&ouml;retr&auml;desemission f&ouml;r att finansiera den fortsatta kommersialiseringen tills dess att man n&aring;r kassafl&ouml;despositivit, vilket f&ouml;rv&auml;ntas ske 2026.&nbsp;Se vd&nbsp;Sofia Heigis&nbsp;ber&auml;tta om [&hellip;]<\/p>\n","protected":false},"featured_media":0,"template":"","news_categories":[],"mfn-news-tag":[174,171,180],"class_list":["post-1278","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn_news\/1278","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media?parent=1278"}],"wp:term":[{"taxonomy":"news_categories","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/news_categories?post=1278"},{"taxonomy":"mfn-news-tag","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn-news-tag?post=1278"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}